Verzistobart

维苏拜单抗

Report date: 2025/06/19 20:00:08

Base Information

Drug NameVerzistobart
Drug Alias NameINCAGN-02390INCAGN-2390
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionHepatitis A virus cellular receptor 2 inhibitors
TargetsHepatitis A virus cellular receptor 2
Therapy Area/IndicationsUveal melanomaGastroesophageal Junction NeoplasmsMicrosatellite instability-high cancer +[22] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAgenus IncIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp
Inactive CompaniesIncyte Biosciences International SàrlUniversity Of Alabama At Birmingham
Active IndicationsGastroesophageal Junction Neoplasms
Inactive IndicationsUveal melanomaMicrosatellite instability-high cancerMismatch Repair Deficient Cancer +[21] 

Other Information

ATC CodeN/A
Related LinksN/A